Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells

Nucleic Acid Therapeutics

Volumn 22, Issue 5, 2012, Pages 295-305

  Ray, Partha ^a   Cheek, Marcus A ^b   Sharaf, Mariam L ^b   Li, Na ^c,d   Ellington, Andrew D ^c   Sullenger, Bruce A ^a   Shaw, Barbara Ramsay ^b   White, Rebekah R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d AM Biotechnologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS CANCER; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIMETABOLITES, ANTINEOPLASTIC; APTAMERS, NUCLEOTIDE; BASE SEQUENCE; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG CARRIERS; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOCYTOSIS; FLUORESCENT DYES; HUMANS; MICROSCOPY, FLUORESCENCE; MOLECULAR SEQUENCE DATA; PANCREATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; STAINING AND LABELING;

EID: 84870357347     PISSN: 21593337     EISSN: None     Source Type: Journal    
DOI: 10.1089/nat.2012.0353     Document Type: Article

References (48)

1. ACHIWA, H., OGURI, T., SATO, S., MAEDA, H., NIIMI, T., and UEDA, R. (2004). Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci. 95, 753-757. (Pubitemid 39335096)
2. BAGALKOT, V., FAROKHZAD, O.C., LANGER, R., and JON, S. (2006). An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem. Int. Ed. Engl. 45, 8149-8152. (Pubitemid 44974149)
3. BATES, P.J., LABER, D.A., MILLER, D.M., THOMAS, S.D., and TRENT, J.O. (2009). Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp. Mol. Pathol. 86, 151-164.
4. BUNKA, D.H., PLATONOVA, O., and STOCKLEY, P.G. (2010). Development of aptamer therapeutics. Curr. Opin. Pharmacol. 10, 557-562.
5. BURRIS, H.A., 3rd, MOORE, M.J., ANDERSEN, J., GREEN, M.R., ROTHENBERG, M.L., MODIANO, M.R., CRIPPS, M.C., PORTENOY, R.K., STORNIOLO, A.M., TARASSOFF, P., et al. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15, 2403-2413. (Pubitemid 27251144)
6. CERCHIA, L., GIANGRANDE, P.H., MCNAMARA, J.O., and DE FRANCISCIS, V. (2009). Cell-specific aptamers for targeted therapies. Methods Mol. Biol. 535, 59-78.
7. CHU, T.C., MARKS, J.W., 3RD, LAVERY, L.A., FAULKNER, S., ROSENBLUM, M.G., ELLINGTON, A.D., and LEVY, M. (2006). Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res. 66, 5989-5992.
8. CONRAD, F., HANNE, A., GAUR, R.K., and KRUPP, G. (1995). Enzymatic synthesis of 2¢-modified nucleic acids: identification of important phosphate and ribose moieties in RNase P substrates. Nucleic Acids Res. 23, 1845-1853.
9. CONROY, T., DESSEIGNE, F., YCHOU, M., BOUCHE, O., GUIMBAUD, R., BECOUARN, Y., ADENIS, A., RAOUL, J.L., GOURGOU-BOURGADE, S., DE LA FOUCHARDIERE, C., et al. (2011). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817-1825.
10. DASSIE, J.P., LIU, X.Y., THOMAS, G.S., WHITAKER, R.M., THIEL, K.W., STOCKDALE, K.R., MEYERHOLZ, D.K., MCCAFFREY, A.P., MCNAMARA, J.O., 2nd, and GIANGRANDE, P.H. (2009). Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat. Biotechnol. 27, 839-849.
11. ELLINGTON, A.D., and SZOSTAK, J.W. (1990). In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818-822.
12. FAROKHZAD, O.C., CHENG, J., TEPLY, B.A., SHERIFI, I., JON, S., KANTOFF, P.W., RICHIE, J.P., and LANGER, R. (2006). Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. U. S. A. 103, 6315-6320.
13. FOWLER, J.D., BROWN, J.A., JOHNSON, K.A., and SUO, Z. (2008). Kinetic investigation of the inhibitory effect of gemcitabine on DNA polymerization catalyzed by human mitochondrial DNA polymerase. J. Biol. Chem. 283, 15339-15348.
14. GAN, H.K., WALKER, F., BURGESS, A.W., RIGOPOULOS, A., SCOTT, A.M., and JOHNS, T.G. (2007). The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806. J. Biol. Chem. 282, 2840-2850. (Pubitemid 47084315)
15. GAUR, R.K., and KRUPP, G. (1993). Modification interference approach to detect ribose moieties important for the optimal activity of a ribozyme. Nucleic Acids Res. 21, 21-26. (Pubitemid 23146288)
16. GIOVANNETTI, E., DEL TACCA, M., MEY, V., FUNEL, N., NANNIZZI, S., RICCI, S., ORLANDINI, C., BOGGI, U., CAMPANI, D., DEL CHIARO, M., et al. (2006). Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 66, 3928-3935.
17. HANSEL, T.T., KROPSHOFER, H., SINGER, T., MITCHELL, J.A., and GEORGE, A.J. (2010). The safety and side effects of monoclonal antibodies. Nat. Rev. Drug Disc. 9, 325-338.
18. HE, K., HASAN, A., KRZYZANOWSKA, B., and SHAW, B.R. (1998). Synthesis and separation of diastereomers of ribonucleoside 5¢-(alpha-P-borano) triphosphates. J. Org. Chem. 63, 5769-5773. (Pubitemid 128491742)
19. HUANG, P., CHUBB, S., HERTEL, L.W., GRINDEY, G.B., and PLUNKETT, W. (1991). Action of 2¢,2¢-difluorodeoxycytidine on DNA synthesis. Cancer Res. 51, 6110-6117.
20. KINDLER, H.L., FRIBERG, G., SINGH, D.A., LOCKER, G., NATTAM, S., KOZLOFF, M., TABER, D.A., KARRISON, T., DACHMAN, A., STADLER, W.M., et al. (2005). Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 23, 8033-8040. (Pubitemid 46657405)
21. KNUDSEN, S.M., ROBERTSON, M.P., and ELLINGTON, A.D. (2002). In vitro selection using modified or unnatural nucleotides. Curr. Protoc. Nucleic Acid Chem. Chapter 9, Unit 9.6.
22. KROEP, J.R., LOVES, W.J., VAN DER WILT, C.L., ALVAREZ, E., TALIANIDIS, I., BOVEN, E., BRAAKHUIS, B.J., VAN GROENINGEN, C.J., PINEDO, H.M., and PETERS, G.J. (2002). Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol. Cancer Ther. 1, 371-376.
23. LEVY-NISSENBAUM, E., RADOVIC-MORENO, A.F., WANG, A.Z., LANGER, R., and FAROKHZAD, O.C. (2008). Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol. 26, 442-449.
24. LI, N., LARSON, T., NGUYEN, H.H., SOKOLOV, K.V., and ELLINGTON, A.D. (2010). Directed evolution of gold nanoparticle delivery to cells. Chemical communications 46, 392-394.
25. LI, N., NGUYEN, H.H., BYROM, M., and ELLINGTON, A.D. (2011). Inhibition of cell proliferation by an anti-EGFR aptamer. PLoS One 6, e20299.
26. LUDWIG, J., and ECKSTEIN, F. (1989). Rapid and efficient synthesis of nucleoside 5¢-O-(1-thiotriphosphate)s, 5¢-triphosphates and 2¢,3¢-cyclophosphorothioates using 2-chloro-4H-1,3,2- benzodioxaphosphorin-4-one. J. Org. Chem. 54, 631-635. (Pubitemid 19060209)
27. MACKEY, J.R., MANI, R.S., SELNER, M., MOWLES, D., YOUNG, J.D., BELT, J.A., CRAWFORD, C.R., and CASS, C.E. (1998). Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res. 58, 4349-4357. (Pubitemid 28450036)
28. MCNAMARA, J.O., 2ND, ANDRECHEK, E.R., WANG, Y., VILES, K.D., REMPEL, R.E., GILBOA, E., SULLENGER, B.A., and GIANGRANDE, P.H. (2006). Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 24, 1005-1015. (Pubitemid 44215395)
29. MILLIGAN, J.F., GROEBE, D.R., WITHERELL, G.W., and UHLENBECK, O.C. (1987). Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates. Nucleic Acids Res. 15, 8783-8798.
30. MOORE, M.J., GOLDSTEIN, D., HAMM, J., FIGER, A., HECHT, J.R., GALLINGER, S., AU, H.J., MURAWA, P., WALDE, D., WOLFF, R.A., et al. (2007). Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960-1966. (Pubitemid 46972777)
31. NAKANO, Y., TANNO, S., KOIZUMI, K., NISHIKAWA, T., NAKAMURA, K., MINOGUCHI, M., IZAWA, T., MIZUKAMI, Y., OKUMURA, T., and KOHGO, Y. (2007). Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br. J. Cancer 96, 457-463. (Pubitemid 46215217)
32. OETTLE, H., POST, S., NEUHAUS, P., GELLERT, K., LANGREHR, J., RIDWELSKI, K., SCHRAMM, H., FAHLKE, J., ZUELKE, C., BURKART, C., et al. (2007). Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. Jama 297, 267-277. (Pubitemid 46143304)
33. OLIVE, K.P., JACOBETZ, M.A., DAVIDSON, C.J., GOPINATHAN, A., MCINTYRE, D., HONESS, D., MADHU, B., GOLDGRABEN, M.A., CALDWELL, M.E., ALLARD, D., et al. (2009). Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461.
34. PADILLA, R., and SOUSA, R. (1999). Efficient synthesis of nucleic acids heavily modified with non-canonical ribose 2¢-groups using a mutantT7 RNA polymerase (RNAP). Nucleic Acids Res. 27, 1561-1563. (Pubitemid 29206303)
35. PATRA, C.R., BHATTACHARYA, R., WANG, E., KATARYA, A., LAU, J.S., DUTTA, S., MUDERS, M., WANG, S., BUHROW, S.A., SAFGREN, S.L., et al. (2008). Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res. 68, 1970-1978. (Pubitemid 351416584)
36. PHILIP, P., BENEDETTI, J., FENOGIO-PREISER, C., ZALUPSKI, M., LENZ, H., O'REILLY, E., WONG, R., ATKINS, J., ABBRUZZESE, J., and BLANKE, C. (2007). Phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma: SWOG S0205 study. J. Clin. Oncol. 25, LBA4509.
37. ROCHA-LIMA, C.M., SOARES, H.P., RAEZ, L.E., and SINGAL, R. (2007). EGFR targeting of solid tumors. Cancer Control 14, 295-304. (Pubitemid 47057800)
38. RUIZ VAN HAPEREN, V.W., VEERMAN, G., VERMORKEN, J.B., and PETERS, G.J. (1993). 2¢,2¢-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem. Pharmacol. 46, 762-766. (Pubitemid 23262974)
39. SIEGEL, R., WARD, E., BRAWLEY, O., and JEMAL, A. (2011). Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 61, 212-236.
40. SOUNDARARAJAN, S., WANG, L., SRIDHARAN, V., CHEN, W., COURTENAY-LUCK, N., JONES, D., SPICER, E.K., and FERNANDES, D.J. (2009). Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells. Mol. Pharmacol. 76, 984-991.
41. SOUSA, R., and PADILLA, R. (1995). A mutant T7 RNA polymerase as a DNA polymerase. EMBO 14, 4609-4621.
42. TUERK, C., and GOLD, L. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505-510.
43. ULLRICH, A., and SCHLESSINGER, J. (1990). Signal transduction by receptors with tyrosine kinase activity. Cell 61, 203-212.
44. VIEIRA, A.V., LAMAZE, C., and SCHMID, S.L. (1996). Control of EGF receptor signaling by clathrin-mediated endocytosis. Science 274, 2086-2089. (Pubitemid 27020702)
45. WICKSTROM, E. (1986). Oligodeoxynucleotide stability in subcellular extracts and culture media. J. Biochem. Biophys. Methods 13, 97-102.
46. XIONG, H.Q., ROSENBERG, A., LOBUGLIO, A., SCHMIDT, W., WOLFF, R.A., DEUTSCH, J., NEEDLE, M., and ABBRUZZESE, J.L. (2004). Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J. Clin. Oncol. 22, 2610-2616. (Pubitemid 41103748)
47. ZHANG, Y., CHEN, Y., HAN, D., OCSOY, I., and TAN, W. (2010). Aptamers selected by cell-SELEX for application in cancer studies. Bioanalysis 2, 907-918.
48. ZHOU, J., and ROSSI, J.J. (2011). Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides 21, 1-10.